Neoagarotetraose (NAT) was shown to modulate GM and thereby attenuate brain damage in mice with Alzheimer’s disease, with a remarkable rise of intestinal bacterial genera (Lactobacillus, Butyricimonas, and Akkermansi) observed after NAT treatment (Li et al., 2023). This evidence concerns the gene BRD2 and early-onset autosomal dominant Alzheimer disease.